Scarica l'app Stockscreener
5.35
3.48%
0.18
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
Lifesci Capital Has Strong Estimate for CMPX FY2025 Earnings - Defense World
Why Compass Therapeutics Inc. stock could outperform in 2025Market Trend Report & Scalable Portfolio Growth Ideas - ulpravda.ru
Will Compass Therapeutics Inc. stock benefit from green energy trendsQuarterly Profit Summary & Low Drawdown Momentum Ideas - ulpravda.ru
Is Compass Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Rallies & Capital Protection Trading Alerts - ulpravda.ru
Short Squeeze: Is Compass Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Daily Volume Surge Signals - ulpravda.ru
Will Compass Therapeutics Inc. stock benefit from commodity prices2025 Fundamental Recap & Weekly Breakout Watchlists - ulpravda.ru
How Compass Therapeutics Inc. stock reacts to global recession fearsEarnings Performance Report & Real-Time Buy Signal Notifications - ulpravda.ru
Is Compass Therapeutics Inc. stock a defensive play in 20252025 Pullback Review & Long-Term Growth Portfolio Plans - ulpravda.ru
Is Compass Therapeutics Inc. stock supported by strong fundamentals2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a Biotech Powerhouse with 142.77% Upside Potential - DirectorsTalk Interviews
Why analysts remain bullish on Compass Therapeutics Inc. stock2025 Investor Takeaways & Reliable Entry Point Alerts - ulpravda.ru
Is Compass Therapeutics Inc. stock in correction or buying zoneMarket Capitalization Trends & Reinvest for Maximum Compounding Returns - ulpravda.ru
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Compass Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Compass Therapeutics details cash runway and pipeline progress - MSN
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Stifel reiterates Buy rating on Compass Therapeutics stock with $12 target - Investing.com Canada
Raymond James reiterates Outperform rating on Compass Therapeutics stock By Investing.com - Investing.com Canada
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Compass Therapeutics reports progress across cancer drug pipeline By Investing.com - Investing.com South Africa
Compass Therapeutics reports progress across cancer drug pipeline - Investing.com
Compass Therapeutics Provides Corporate Update - GlobeNewswire
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026 - MarketScreener
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation - Nasdaq
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care - One News Page
Compass Therapeutics announces key leadership appointments - MarketScreener
Compass Therapeutics appoints new chief commercial and medical officers - Investing.com
Compass Therapeutics Announces Key Leadership Appointments - The Manila Times
William Blair Initiates Compass Therapeutics at Outperform - MarketScreener
William Blair initiates coverage on Compass Therapeutics stock with Outperform rating - Investing.com Canada
Which Way Will The Needle Swing For Compass Therapeutics' Biliary Tract Cancer Study? - RTTNews
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - MSN
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next? - Defense World
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5%What's Next? - MarketBeat
Compass Therapeutics files for up to $400 million mixed shelf offeringSEC filing - MarketScreener
Compass Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Wedbush Remains a Buy on Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics’ (CMPX) Tovecimig Drives Strong Analyst Sentiment - Insider Monkey
Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment - Finviz
Published on: 2025-12-21 11:19:43 - moha.gov.vn
Compass Therapeutics Earnings Notes - Trefis
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance
12 Best Multibagger Stocks to Buy Heading into 2026 - Insider Monkey
Patterns Watch: How Compass Therapeutics Inc. stock reacts to global recession fearsPrice Action & Low Risk Profit Maximizing Plans - DonanımHaber
How Compass Therapeutics Inc. stock trades during market volatilityWeekly Stock Recap & Comprehensive Market Scan Reports - Улправда
Signal Recap: Is Compass Therapeutics Inc. stock in correction or buying zone2025 Earnings Impact & Low Drawdown Investment Ideas - ulpravda.ru
Published on: 2025-12-19 03:17:09 - Улправда
Published on: 2025-12-19 02:57:37 - Улправда
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference - Yahoo Finance
Wall Street analysts think Compass Therapeutics, Inc. (CMPX) could surge 134.14%: Read this before placing a bet - MSN
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):